ライフサイエンスコーパス: alloimmunization

1 le effect on primary T-cell reactivity after alloimmunization.

2 oimmunization and for abolishing established alloimmunization.

3 proved oxygenation, with a 1 percent rate of alloimmunization.

4 at risk for anemia due to maternal red-cell alloimmunization.

5 at risk for anemia due to maternal red-cell alloimmunization.

6 major complication of transfusion therapy is alloimmunization.

7 ocytes provides a potential stimulus for HbA alloimmunization.

8 antigen features that may also influence RBC alloimmunization.

9 tic counseling and prenatal assessment of Rh alloimmunization.

10 nts should be considered to prevent platelet alloimmunization.

11 as a means of preventing the development of alloimmunization.

12 a good serologic screen for the diagnosis of alloimmunization.

13 of an adjuvant, is sufficient to induce RBC alloimmunization.

14 eceptor is required for inflammation-induced alloimmunization.

15 significantly decreased in Akita mice after alloimmunization.

16 4 expression, thereby confirming its role in alloimmunization.

17 c acid-induced IFN-alpha/beta production and alloimmunization.

18 Prophylactic protocols prevented alloimmunization.

19 inflammatory state that is less conducive to alloimmunization.

20 ti-CD20 Ab has recently been used to prevent alloimmunization.

21 unknown to what extent this occurs in human alloimmunization.

22 ens, whereas nonresponders were resistant to alloimmunization.

23 nicity is a crucial factor in red blood cell alloimmunization.

24 binding motif for HLA-DR52a that can lead to alloimmunization.

25 mental factors may play a role in regulating alloimmunization.

26 mmation has a complex regulatory effect upon alloimmunization.

27 mit the further amplification of established alloimmunization.

28 mmation in mice has the capacity to regulate alloimmunization.

29 d the enhancing effects of poly (I:C) on RBC alloimmunization.

30 l leukocytes in blood transfusions can cause alloimmunization.

31 mmatory conditions associated with increased alloimmunization.

32 acid [poly (I:C)] significantly enhances RBC alloimmunization.

33 ion and, (5) the treatment and prevention of alloimmunization.

34 in 60%) proved to be effective in preventing alloimmunization (2.8% vs 33%; P =.0005).

35 alloimmunization was more prevalent than RBC alloimmunization (20% to 30%).

36 with such a microbe could predispose to RBC alloimmunization, a mouse model was developed using muri

37 Alloimmunization against RBCs can cause life-threatening

38 However, transfusions can trigger alloimmunization against transfused RBCs with serious cl

39 Alloimmunization and autoimmunization are common, seriou

40 We assessed protocols for preventing primary alloimmunization and for abolishing established alloimmu

41 m)IL-12 was given to C57BL/6 mice undergoing alloimmunization and found to transiently but profoundly

42 from transfusion or pregnancy, may result in alloimmunization and incompatible RBC clearance.

43 specificity, and transfusions are limited by alloimmunization and iron overload.

44 We used BALB/c donors (H-2(d)) to assess alloimmunization and islet transplantation outcomes in A

45 quiring transfusion with a very high risk of alloimmunization and life-threatening complications.

46 nfections, may have an increased risk of RBC alloimmunization and may benefit from personalized trans

47 le blood group loci, potentially eliminating alloimmunization and significantly improving transfusion

48 used leukocytes is critical to prevention of alloimmunization and transfusion-induced graft-versus-ho

49 ved antimicrobials, the effects of recipient alloimmunization and variable cell dose.

50 Autoimmunization was associated with alloimmunization and with the absence of spleen (44% and

51 transfused blood has been shown to decrease alloimmunization, and genotyping for antigen matching ma

52 ion, neonatal sepsis, twin-twin transfusion, alloimmunization, and hemolytic disease.

53 ction of platelet products, prevention of Rh alloimmunization, and management of refractoriness to pl

54 tients to insufficient correction of anemia, alloimmunization, and organ iron overload (for which the

55 ients, but immune factors governing risk for alloimmunization are unknown.

56 c patient databases enabling us to model RBC alloimmunization as a stochastic process.

57 commonly used therapy but has limitations of alloimmunization, availability, and expense.

58 Transfusion resulted in iron overload and alloimmunization, but no infection.

59 the ability of Mirasol treatment to prevent alloimmunization by platelet transfusions in rats.

60 RBC alloimmunization can present a special challenge to soli

61 Alloimmunization can present a virtually insurmountable

62 HPA-1a alloimmunization complicates 1 in 350 unselected pregnan

63 k of three complications of transfusion: HLA alloimmunization, cytomegalovirus transmission, and recu

64 Moreover, preoperative alloimmunization did not block tolerance induction or in

65 ity/mortality of HDFN, women at risk for RBC alloimmunization have few therapeutic options.

66 Cases had a positive history of alloimmunization, having received >/=1 RBC unit.

67 Controls had a negative history of alloimmunization, having received >/=20 RBC units.

68 Keywords included platelet transfusion, alloimmunization, hemorrhage, threshold and thrombocytop

69 Transfusions can lead to erythrocyte alloimmunization, however, with serious complications fo

70 eral concerns, including the consequences of alloimmunization in chronically transfused patients and

71 rphism have over a 3-fold lower risk for RBC alloimmunization in comparison with patients without thi

72 Advances have been made in understanding alloimmunization in granulocyte transfusion recipients a

73 carry out studies of prophylaxis to prevent alloimmunization in HPA-1a-negative mothers.

74 the rate and the frequency of red blood cell alloimmunization in mouse models, may dictate responder/

75 report results of prospective monitoring for alloimmunization in our recent CBT experience.

76 These data describe the prevalence of Rh alloimmunization in patients with SCD transfused with ph

77 port findings from an observational study of alloimmunization in patients with sickle cell disease (S

78 Extended blood typing decreases alloimmunization in SCD but is not universally adopted.

79 patients and minority donors will reduce Rh alloimmunization in SCD needs to be examined.

80 Risk factors for alloimmunization in SCD remain poorly understood.

81 on between genetic variation of FCGR and RBC alloimmunization in SCD.

82 This may provide a means to prevent alloimmunization in the setting of RBC transfusion and s

83 patients and in the donors contributed to Rh alloimmunization in this study.

84 olyclonal anti-KEL sera completely prevented alloimmunization in wild-type and single-knockout (KO) m

85 laxis with polyclonal anti-KEL sera prevents alloimmunization in wild-type recipients transfused with

86 Alloimmunization is a major problem for patients being c

87 Red blood cell (RBC) alloimmunization is a serious complication of transfusio

88 ntly occurring phenomenon, prevention of HLA alloimmunization is an important management strategy.

89 bulin to prevent pregnancy associated anti-D alloimmunization, its mechanism of action remains elusiv

90 unologic consequences of transfusion such as alloimmunization may also be severe, resulting in acute

91 However, alloimmunization may be a concern with adjuvanted vaccin

92 background peptide responses independent of alloimmunization may contribute to K immunogenicity.

93 hat are at risk because of maternal red-cell alloimmunization, moderate and severe anemia can be dete

94 untransfused patients demonstrated platelet alloimmunization (P < .05).

95 As in humans, RBC alloimmunization rates in recipient mice are variable, w

96 Red blood cell alloimmunization remains a major complication for transf

97 fractory to platelet transfusions because of alloimmunization require HLA-matched platelets, which is

98 RF) was strongly associated with a decreased alloimmunization risk (odds ratio [OR] 0.26, 95% confide

99 t donor RBC antigens, and valid estimates of alloimmunization risk are clinically important, but litt

100 s or patients with a known predisposition to alloimmunization, such as those with sickle cell disease

101 childhood are associated with lower rates of alloimmunization than are seen in SCD, suggesting immune

102 s who had a splenectomy had a higher rate of alloimmunization than patients who did not have a splene

103 ts that has a dramatically increased risk of alloimmunization that appears to be genetically determin

104 ing mixed lymphocyte reactions as a model of alloimmunization, the authors assessed the effect of inf

105 platelet concentrates for prevention of HLA alloimmunization, the findings of this study support tha

106 To discuss how inflammation affects humoral alloimmunization to antigens on transfused red blood cel

107 ay a significant role in transfusion-induced alloimmunization to donor class-I MHC antigens.

108 MNL) are responsible for transfusion-induced alloimmunization to donor major histocompatability compl

109 Human lymphocyte antigen alloimmunization to filter leukoreduced (F-LR) platelets

110 cessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohema

111 of the fetus and newborn (HDFN) is caused by alloimmunization to paternally derived RBC antigens.

112 In the Trial to Reduce Alloimmunization to Platelets (TRAP) study, 101 of 530 p

113 given to 533 patients in the Trial to Reduce Alloimmunization to Platelets (TRAP).

114 MT, we wished to determine the prevalence of alloimmunization to platelets in transfused SCD patients

115 Results of the Trial to Reduce Alloimmunization to Platelets will be reported shortly a

116 a similar role of inflammation in regulating alloimmunization to RBCs.

117 Alloimmunization to red blood cell (RBC) antigens can si

118 Humoral alloimmunization to red blood cell (RBC) antigens is a c

119 s been most applied are fetal aneuploidy and alloimmunization to red blood cell antigens.

120 ently, three unique murine models of humoral alloimmunization to transfused RBCs have been described.

121 to investigate if similar biology regulates alloimmunization to transfused RBCs in humans.

122 sm by which viral-like inflammation enhances alloimmunization to transfused RBCs.

123 velopment of refractoriness to transfusions, alloimmunization, transfusion reactions, the transmissio

124 variety of immunologic responses, including alloimmunization, transfusion-associated graft-versus-ho

125 onor for male recipient, donor parity, donor alloimmunization, viral serology, nucleated cell dose, C

126 te) and Asian recipients on the frequency of alloimmunization was determined.

127 Platelet alloimmunization was more prevalent than RBC alloimmuniz

128 minority of untransfused patients at risk of alloimmunization who would benefit from more extensively

129 we discuss the risk factors associated with alloimmunization with emphasis on possible mechanisms th

130 7BL/6 splenocytes taken 7 days after in vivo alloimmunization with irradiated BALB/c spleen cells.